company background image
DGX

Quest DiagnosticsNYSE:DGX Stock Report

Market Cap

US$18.7b

7D

-1.1%

1Y

37.1%

Updated

25 Sep, 2021

Data

Company Financials +
DGX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance6/6
Financial Health4/6
Dividends5/6

DGX Overview

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally.

Quest Diagnostics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Quest Diagnostics
Historical stock prices
Current Share PriceUS$153.09
52 Week HighUS$109.50
52 Week LowUS$160.56
Beta1.03
1 Month Change2.34%
3 Month Change18.10%
1 Year Change37.06%
3 Year Change41.87%
5 Year Change80.89%
Change since IPO4,274.00%

Recent News & Updates

Shareholder Returns

DGXUS HealthcareUS Market
7D-1.1%-2.2%0.1%
1Y37.1%33.6%35.3%

Return vs Industry: DGX exceeded the US Healthcare industry which returned 33.6% over the past year.

Return vs Market: DGX exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is DGX's price volatile compared to industry and market?
DGX volatility
DGX Beta1.03
Industry Beta0.87
Market Beta1

Stable Share Price: DGX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: DGX's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196744,500Steve Rusckowskihttps://www.questdiagnostics.com

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.

Quest Diagnostics Fundamentals Summary

How do Quest Diagnostics's earnings and revenue compare to its market cap?
DGX fundamental statistics
Market CapUS$18.70b
Earnings (TTM)US$2.24b
Revenue (TTM)US$11.06b

8.4x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DGX income statement (TTM)
RevenueUS$11.06b
Cost of RevenueUS$6.44b
Gross ProfitUS$4.62b
ExpensesUS$2.38b
EarningsUS$2.24b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)18.32
Gross Margin41.74%
Net Profit Margin20.24%
Debt/Equity Ratio66.6%

How did DGX perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

14%

Payout Ratio

Does DGX pay a reliable dividends?

See DGX dividend history and benchmarks
When do you need to buy DGX by to receive an upcoming dividend?
Quest Diagnostics dividend dates
Ex Dividend DateOct 04 2021
Dividend Pay DateOct 20 2021
Days until Ex dividend8 days
Days until Dividend pay date24 days

Does DGX pay a reliable dividends?

See DGX dividend history and benchmarks

Valuation

Is Quest Diagnostics undervalued compared to its fair value and its price relative to the market?

8.36x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DGX ($153.09) is trading above our estimate of fair value ($111.41)

Significantly Below Fair Value: DGX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DGX is good value based on its PE Ratio (8.4x) compared to the US Healthcare industry average (21.9x).

PE vs Market: DGX is good value based on its PE Ratio (8.4x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: DGX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: DGX's PB Ratio (3.2x) is in line with the US Healthcare industry average.


Future Growth

How is Quest Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

-31.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DGX's earnings are forecast to decline over the next 3 years (-31.3% per year).

Earnings vs Market: DGX's earnings are forecast to decline over the next 3 years (-31.3% per year).

High Growth Earnings: DGX's earnings are forecast to decline over the next 3 years.

Revenue vs Market: DGX's revenue is expected to decline over the next 3 years (-6.1% per year).

High Growth Revenue: DGX's revenue is forecast to decline over the next 3 years (-6.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DGX's Return on Equity is forecast to be low in 3 years time (15.9%).


Past Performance

How has Quest Diagnostics performed over the past 5 years?

19.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DGX has high quality earnings.

Growing Profit Margin: DGX's current net profit margins (20.2%) are higher than last year (9.9%).


Past Earnings Growth Analysis

Earnings Trend: DGX's earnings have grown by 19.2% per year over the past 5 years.

Accelerating Growth: DGX's earnings growth over the past year (198.8%) exceeds its 5-year average (19.2% per year).

Earnings vs Industry: DGX earnings growth over the past year (198.8%) exceeded the Healthcare industry 32.2%.


Return on Equity

High ROE: DGX's Return on Equity (38.9%) is considered high.


Financial Health

How is Quest Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: DGX's short term assets ($2.1B) exceed its short term liabilities ($1.6B).

Long Term Liabilities: DGX's short term assets ($2.1B) do not cover its long term liabilities ($5.3B).


Debt to Equity History and Analysis

Debt Level: DGX's debt to equity ratio (66.6%) is considered high.

Reducing Debt: DGX's debt to equity ratio has reduced from 82.4% to 66.6% over the past 5 years.

Debt Coverage: DGX's debt is well covered by operating cash flow (64.7%).

Interest Coverage: DGX's interest payments on its debt are well covered by EBIT (18.3x coverage).


Balance Sheet


Dividend

What is Quest Diagnostics's current dividend yield, its reliability and sustainability?

1.62%

Current Dividend Yield


Upcoming Dividend Payment

TodaySep 26 2021Ex Dividend DateOct 04 2021Dividend Pay DateOct 20 202116 days from Ex DividendBuy in the next 8 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: DGX's dividend (1.62%) is higher than the bottom 25% of dividend payers in the US market (1.33%).

High Dividend: DGX's dividend (1.62%) is low compared to the top 25% of dividend payers in the US market (3.6%).


Stability and Growth of Payments

Stable Dividend: DGX's dividends per share have been stable in the past 10 years.

Growing Dividend: DGX's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (13.9%), DGX's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: DGX's dividends in 3 years are forecast to be well covered by earnings (27.4% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average management tenure


CEO

Steve Rusckowski (64 yo)

9.33yrs

Tenure

US$14,081,608

Compensation

Mr. Stephen H. Rusckowski, also known as Steve, has been the Chief Executive Officer, President and Director of Quest Diagnostics Incorporated since May 1, 2012 and has been its Chairman since January 1, 2...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD14.08M) is about average for companies of similar size in the US market ($USD11.36M).

Compensation vs Earnings: Steve's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: DGX's management team is seasoned and experienced (8.3 years average tenure).


Board Members

Experienced Board: DGX's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Quest Diagnostics Incorporated's employee growth, exchange listings and data sources


Key Information

  • Name: Quest Diagnostics Incorporated
  • Ticker: DGX
  • Exchange: NYSE
  • Founded: 1967
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$18.705b
  • Shares outstanding: 122.18m
  • Website: https://www.questdiagnostics.com

Number of Employees


Location

  • Quest Diagnostics Incorporated
  • 500 Plaza Drive
  • Secaucus
  • New Jersey
  • 7094
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 22:07
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.